1537 NW 65th Avenue ◆ Plantation, Florida 33313
Office (954) 509-0911 ◆ Fax (877) 895-5647

January 17, 2022

Dear Fellow Shareholders of Nutra Pharma:

As we have persevered through another pandemic year of 2021; we are looking forward to a much brighter 2022. I want to take this opportunity to update you on the current status of the Company, provide a review of 2021 and briefly outline our goals and expectations for the coming months.

Nutra Pharma Corporation operates as a biotechnology company specializing in products and technologies for the management of neurological disorders, autoimmune, and infectious diseases, including Multiple Sclerosis (MS), Human Immunodeficiency Virus (HIV) and Pain. We recently announced the use of our technology as potential nerve agent counter-measures. Additionally, the Company markets drug products for sale for the treatment of pain under the brands Nyloxin®, Equine Pain-Away™, Luxury Feet™ and Pet Pain-Away™.

Even through the pandemic crises of 2021, we accomplished the following throughout the year:

- We renewed our focus on our intellectual property portfolio and engaged new IP attorneys at Christopher & Weisberg P.A. As part of this effort, we filed a new provisional patent to protect our intellectual property surrounding our development of nerve agent counter measures.
- We improved our existing facilities for manufacturing and validation of our drug products. This included the renewal of our lease for our current lab space and bringing all of our manufacturing in-house.
- We engaged AccuReg, Inc. as outside Regulatory and Quality Assurance consultants as part of our work in improving our existing facilities for manufacturing and validation of our drug products.
- We began the marketing and distribution of *Luxury Feet;* an over-the-counter pain reliever and anti-inflammatory product that is designed for women who experience pain or discomfort due to high heels and stilettos. *Luxury Feet* is currently available in several storefronts as well as on Amazon.
- We began expanding the marketing of our over-the-counter pain relievers and anti-inflammatory products by working with influencers on several social media platforms. This includes celebrities as well as professional and Olympic athletes that have benefitted from our products. We have already announced professional snowboarder Jake Vedder as a celebrity endorser and Nyloxin user.
- We greatly increased our manufacturing capabilities for the production of our line of over-the-counter pain relievers and anti-inflammatory drugs. As part of this process, we completed the design and purchase for a new liquid filling line that includes automatic filling, capping, coding, labeling and heat shrinking for most of our products. The equipment was validated, certified and in production in August of 2021.
- We announced our plans for increasing sales of our over-the-counter pain relievers through private label agreements that will rebrand Nyloxin. The first private label distributor contract has been executed with sales expected throughout 2022. Their marketing plan includes direct sales, targeted landing pages and aggressive marketing through social media.
- We announced that Diverse Health Services of Metro-Detroit has added the Nyloxin line of products to their offerings. Nyloxin is being sold in-house at their facilities as well as their online marketplace. Their marketing plan includes direct sales to patients and other medical facilities, sales through their websites and social media utilizing their online platforms as well as videos featuring Dr. Randall Tent.
- We engaged the Washington DC-based government affairs consulting firm, Vitello Consulting. The firm has been working with elected officials as well as governmental agencies to increase the awareness of Nutra Pharma's products and technologies with the goal of improving sales, garnering grants and potentially speeding drug applications.

Throughout 2022, we expect to continue actively marketing Nyloxin, Pet Pain-Away, Luxury Feet and Equine Pain-Away. We are currently working to begin a broad retail rollout with all of our products as well as new private label brands that utilize our technologies. These sales will bring in the revenue that will bring the company to profitability as well as provide the financing for the proposed clinical studies.

In 2022, we plan to begin clinical trials with our Multiple Sclerosis (MS) drug, RPI-78M. These trials will include a Phase II trial in adult patients as well as a Phase I/II trial under our Orphan designation for pediatric MS. The Orphan status of the drug will allow for faster, less expensive trials as we lay the groundwork for the eventual drug production and trial protocol development. It is our goal to complete the Phase I/II trials in pediatric MS over the next 18-24 months and then either move into Phase III trials or seek a licensing partner. We also plan to move forward with our work in nerve agent counter-measures and have been working with US governmental agencies to fund that work.

This is an exciting time for the company as we create manufacturing jobs, launch new products and begin to effectively market our entire line of analgesics. We are also working with outside companies as product formulators and contract manufacturers to further utilize our increased lab and manufacturing capabilities. This is another revenue stream for the company that has already seen growth over the last quarter. We truly believe that we've created the perfect environment for *real, sustainable growth* for our products and our technologies that will appeal to a global market in the coming months.

If you haven't already taken a moment to sign up for our e-mail alerts, be sure to do so by visiting our website. Signing up will ensure that you receive the latest news and announcements when they become available. As always, if you have any additional questions or would like more information, please contact our investor relations' hotline at (877) 895-5647.

Sincerely yours,

Rik J. Deitsch
Chairman and Chief Executive Officer
Nutra Pharma Corporation; Stock Symbol: NPHC

This letter contains forward-looking statements. The words or phrases "would be," "will allow," "intends to," "will likely result," "are expected to," "will continue," "is anticipated," "estimate," "project," or similar expressions are intended to identify "forward-looking statements." Actual results could differ materially from those projected in Nutra Pharma's ("the Company") business plan. The Company's business is subject to various risks, which are discussed in the Company's filings with the Securities and Exchange Commission ("SEC"). This shareholder letter should not be construed as an indication in any way whatsoever of the value of the Company or its common stock. The Company's filings may be accessed at the SEC's Edgar system at www.sec.gov. Statements made herein are as of the date of this shareholder letter and should not be relied upon as of any subsequent date. The Company cautions readers not to place reliance on such statements. Unless otherwise required by applicable law, we do not undertake, and we specifically disclaim any obligation, to update any forward-looking statements to reflect occurrences, developments, unanticipated events or circumstances after the date of such statement.